Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
BUSINESS
Fuji Pharma/M3’s Dysmenorrhea Drug Hits Main PIII Goal; 2024 Launch Eyed
Fuji Pharma and M3 said on February 9 that their investigational fixed-dose combination treatment estetrol/drospirenone (FSN-013) achieved the primary endpoints in two Japan PIII studies respectively for dysmenorrhea and endometriosis. They aim for its launch in 2024.The two companies inked…
To read the full story
Related Article
- Fuji Pharma Kicks Off Japan PIII for Alyssa in Endometriosis
July 28, 2025
- Fuji Pharma/M3’s Dysmenorrhea Drug Filed in Japan, 2024 Rollout Targeted
October 19, 2023
- Herceptin Biosimilars Get Colorectal Cancer Nod: Celltrion, Nippon Kayaku
October 19, 2023
- Fuji Pharma, M3 Join Hands on Dysmenorrhea Med in Japan
November 13, 2020
BUSINESS
- Forxiga Exit Weighs on Ono’s Japan Sales, but Boosts Profit
August 3, 2026
- Bayer, JFCR Ink Strategic Oncology R&D Partnership
August 3, 2026
- CSL Debuts Higher-Dose Hizentra Prefilled Syringe in Japan
August 3, 2026
- Taisho Bags Japan Rights to Kaigene’s FcRn Inhibitor KG006
August 3, 2026
- Datroway Lands EU Approval in 1st-Line TNBC
August 3, 2026
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Adeno-associated virus (AAV) gene therapies have long been viewed as carrying only a minimal risk of insertional mutagenesis — a…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…